Keywords: reopro, plus, thrombolysis, improves, arterial, patency, final
ReoPro plus thrombolysis improves arterial patency; final TIMI 14 results
Article | 03 June 1999
The combination of Centocor/Eli Lilly's platelet glycoprotein IIb/IIIaantagonist ReoPro (abciximab) and a low-dose regimen of Genentech's thrombolytic Activase ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
